How does antibody-drug conjugate (ADC) therapy work for Prostate Cancer

How Antibody-Drug Conjugate (ADC) Therapy Works for Prostate Cancer

The Basic Mechanism

An antibody-drug conjugate is essentially a targeted delivery system for cancer-fighting drugs. Think of it as a "smart bomb" that delivers chemotherapy directly to cancer cells while minimizing damage to healthy tissue.

Here's how it works in three steps:

STEP 1 - THE ANTIBODY FINDS THE TARGET The antibody portion of the ADC is designed to recognize and bind to a specific protein on the surface of prostate cancer cells. For example, some ADCs target B7-H3 (also called CD276), a protein that's overexpressed on prostate cancer cells.

STEP 2 - THE DRUG GETS DELIVERED Once the antibody binds to the cancer cell, the entire ADC gets pulled inside the cell through a process called internalization. This is the key advantage—the toxic payload stays attached during transport and only gets released inside the cancer cell.

STEP 3 - THE PAYLOAD DOES ITS JOB Once inside, the linker (the connector between antibody and drug) breaks down, releasing the toxic agent. Different ADCs use different payloads:

• Some use tubulin inhibitors (drugs that disrupt the cell's structural framework)
• Newer ones use TOPO1 inhibitors (drugs that prevent DNA repair and cell division)

Why This Matters for Prostate Cancer

According to the CancerPatientLab webinar on "Clinical Guidance from Proteomics," some ADCs have an additional advantage called "bystander activity"—meaning the toxic drug can actually escape the cancer cell and kill neighboring cancer cells too. This can make the treatment more effective.

Current ADC Options Being Studied in Prostate Cancer

Several ADCs are in clinical development for prostate cancer, targeting different surface proteins:

• B7-H3-targeted ADCs (like those from Daiichi Sankyo) - These are entering clinical trials
• PSMA-targeted ADCs - Targeting prostate-specific membrane antigen
• TROP-2-targeted ADCs - Targeting another surface protein
• STEAP1-targeted ADCs - Targeting a prostate-specific cell surface antigen
• HER2-targeted ADCs - Including trastuzumab deruxtecan (Enhertu)

HER2 Expression in Prostate Cancer: An Emerging Opportunity

Here's something particularly interesting: According to the proteomics webinar, researchers examined HER2 protein levels in prostate cancer samples and found:

• About 40% had no detectable HER2
• 3-5 patients had high HER2 levels (potentially eligible for anti-HER2 therapies)
• A significant portion had low HER2 expression

This is important because trastuzumab deruxtecan (Enhertu), an anti-HER2 ADC, recently showed promise in patients with "HER2-low" cancers in breast cancer trials. There's now a clinical trial combining this drug with a PARP inhibitor for prostate cancer patients with HER2 expression.

Important Biomarker Considerations

Knowing your protein expression matters. If you have high expression of the target protein (like B7-H3 or HER2), you're more likely to benefit from an ADC targeting that protein. However, the webinar notes that simply having the target present isn't always enough—resistance mechanisms inside the cell can sometimes prevent the drug from working effectively.

Current Clinical Development Status

According to the "Update on Prostate Cancer Treatments" webinar, ADCs for prostate cancer are still largely in clinical trials. The field is actively developing these therapies, but more data is needed to determine which ADCs will become standard treatment options.

Questions to Ask Your Oncologist

If ADC therapy is being considered for your situation:

1. Has my tumor been tested for the specific protein targets (B7-H3, HER2, PSMA, TROP-2, STEAP1)? This testing helps determine which ADCs might be appropriate.

2. Are there clinical trials available for ADC therapy that match my specific protein expression profile?

3. What are the expected side effects of the specific ADC being recommended, and how do they compare to my other treatment options?

4. How will we monitor whether the ADC is working? (PSA levels, imaging, other biomarkers)

5. If this ADC doesn't work, what are my next treatment options?

The Bottom Line

ADC therapy represents an important innovation in prostate cancer treatment—it's a way to deliver powerful drugs more precisely to cancer cells. However, this is still an evolving field. Your specific protein expression profile, the stage of your cancer, and your previous treatments all influence whether an ADC would be appropriate for you.

According to the CancerPatientLab webinars on prostate cancer treatments, the field is moving toward more personalized approaches where treatment selection is based on your individual tumor's characteristics, rather than a "one-size-fits-all" approach.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.